Status:
COMPLETED
A Study of Radiation With Sorafenib in Advanced Cancer
Lead Sponsor:
University Health Network, Toronto
Conditions:
Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
The purpose of this study is to test the combination of radiation treatment and an anti-angiogenic drug called sorafenib (or BAY 43-9006 or Nexavar) to determine the effects of this combination on can...
Eligibility Criteria
Inclusion
- Advanced cancer not eligible for curative treatment.
- A measurable lesion in the thorax, abdomen or pelvis.
- Normal organ and bone marrow function.
- Able to receive protocol prescribed radiation. Please refer to the protocol for detailed inclusion criteria.
Exclusion
- Overlap of treatment field with a previous radiation field.
- Inability to meet mandated normal tissue radiation dose constraints.
- Brain metastases (unless previously treated and controlled)
- Previous treatment with Sorafenib.
- Poorly controlled Hypertension.
- Unable to swallow sorafenib tablets.
- Intercurrent cardiac dysfunction.
- Uncontrolled intercurrent illness. Please refer to the protocol for detailed exclusion criteria.
Key Trial Info
Start Date :
May 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2011
Estimated Enrollment :
34 Patients enrolled
Trial Details
Trial ID
NCT00610246
Start Date
May 1 2007
End Date
May 1 2011
Last Update
February 15 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Princess Margaret Hospital
Toronto, Ontario, Canada, M5G 2M9